KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Non-Current Debt (2018 - 2021)

Bionano Genomics (BNGO) has disclosed Non-Current Debt for 4 consecutive years, with $14.9 million as the latest value for Q1 2021.

  • Quarterly Non-Current Debt changed N/A to $14.9 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $14.9 million through Mar 2021, changed N/A year-over-year, with the annual reading at $16.3 million for FY2020, N/A changed from the prior year.
  • Non-Current Debt hit $14.9 million in Q1 2021 for Bionano Genomics, down from $16.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $18.8 million in Q3 2019 to a low of $1.8 million in Q2 2020.
  • Historically, Non-Current Debt has averaged $12.1 million across 4 years, with a median of $14.9 million in 2021.
  • Biggest five-year swings in Non-Current Debt: soared 108.44% in 2019 and later tumbled 90.55% in 2020.
  • Year by year, Non-Current Debt stood at $9.0 million in 2018, then soared by 107.96% to $18.8 million in 2019, then decreased by 13.06% to $16.3 million in 2020, then dropped by 8.94% to $14.9 million in 2021.
  • Business Quant data shows Non-Current Debt for BNGO at $14.9 million in Q1 2021, $16.3 million in Q4 2020, and $1.8 million in Q3 2020.